Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Nov 28;18(1):570.
doi: 10.1186/s13063-017-2309-5.

The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial

Ida Kristiane Roelsgaard  1 , Thordis Thomsen  2   3 , Mikkel Østergaard  4   3 , Robin Christensen  5 , Merete Lund Hetland  4   3   6 , Søren Jacobsen  3   7 , Lena Andersen  8 , Hanne Tønnesen  9   10   11 , Silvia Rollefstad  12 , Anne Grete Semb  12 , Bente Appel Esbensen  4   3
Affiliations
Randomized Controlled Trial

The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial

Ida Kristiane Roelsgaard et al. Trials. .

Abstract

Background: Rheumatoid arthritis (RA) is a chronic, inflammatory rheumatic disease with the potential to induce significant disability. Patients with RA are at increased risk of cardiovascular diseases (CVD). Smokers with RA tend to experience more pain and fatigue, higher disease activity, more erosive joint destruction and a lower health-related quality of life (HR-QoL) than non-smokers. It remains to be determined whether these effects can be reduced by smoking cessation. This randomised controlled trial (RCT) in patients with RA aims to examine the effect of intensive smoking cessation intervention (motivational counselling combined with tailored nicotine replacement therapy) versus standard care on smoking cessation, and consequently on disease activity. Secondary objectives are to explore the effect on flare, risk factors for CVD, lung function, physical function, HR-QoL, pain and fatigue in patients with RA.

Methods: This will be a multicentre, open label, two arm, parallel group, RCT, including 150 daily smokers with RA, being in remission or having low-moderate disease activity (DAS28 ≤ 5.1). The intervention group (n = 75) will receive five counselling sessions with a trained smoking cessation counsellor based on the principles of motivational counselling. Furthermore, intervention patients will be offered nicotine replacement therapy tailored to individual needs. Participants randomised to the control group will receive standard care. The co-primary outcome is a hierarchical endpoint, which will be evaluated at 3 months follow-up and will include (1) self-reported smoking cessation biochemically validated by exhaled carbon monoxide and (2) achievement of EULAR clinical response (an improvement in DAS28 of > 0.6). Follow-up visits will be performed at 3, 6 and 12 months post-intervention.

Discussion: This trial will reveal whether intensive smoking cessation counselling helps smokers with RA to achieve continuous smoking cessation and whether, as a concomitant benefit, it will reduce their RA disease activity. The trial aims to generate high quality evidence for the feasibility of a health promotion intervention for smokers with RA.

Trial registration: ClinicalTrials.gov, identifier: NCT02901886 . Registered on 10 September 2016. Recruitment status updated on 10th October 2016.

Keywords: Behavioural change; Cardiovascular biomarkers; Cardiovascular disease; Clinical health promotion; Flare; Health-related quality of life; Motivational counselling; Nicotine replacement therapy; Smoking cessation intervention; Tobacco smoking.

PubMed Disclaimer

Conflict of interest statement

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
CONSORT Flow diagram: recruitment, screening and enrolment
Fig. 2
Fig. 2
SPIRIT figure
See this image and copyright information in PMC

References

    1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41(7):793–800. doi: 10.1093/rheumatology/41.7.793. - DOI - PubMed
    1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108. doi: 10.1016/S0140-6736(10)60826-4. - DOI - PubMed
    1. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000;39(Suppl 2):3–12. doi: 10.1093/rheumatology/39.suppl_2.3. - DOI - PubMed
    1. Hewlett S, Sanderson T, May J, Alten R, Bingham CO, Cross M, et al. ‘I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012;51(1):69–76. doi: 10.1093/rheumatology/keq455. - DOI - PubMed
    1. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient’s perspective. J Rheumatol. 2003;30(4):880–3. - PubMed

Publication types

MeSH terms

Associated data